Browsing by Subject "Breast carcinoma"

Article

The clinical significance of bcl-2 overexpression in breast cancer patients - A retrospective study with long term follow up

Bai, M. C.; Agnantis, Niki J.; Zagorianakou, P.; Kamina, S.; Nonni, A. V.; Pavlidis, Nicholas; Briassoulis, E. Ch (2001)

We examined by immunohistochemistry the expression of the bcl-2 protein in sixty-eight cases of operated breast carcinoma patients (stage I, II and III) and correlated the findings with the prognosis. In 38.3% of the cases ...

Article

Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. Correlation with extracellular matrix components

Tsanou, E.; Ioachim, E.; Briassoulis, E. Ch; Charchanti, A.; Damala, K.; Karavasilis, V.; Pavlidis, Nicholas; Agnantis, Niki J. (2004)

Syndecan-1, a cell surface proteoglycan found predominantly on epithelia of mature tissues, binds both extracellular matrix (ECM) components and basic fibroblast growth factor (bFGF) and is implicated in the restriction ...

Article

Effect of letrozole on the lipid profile in postmenopausal women with breast cancer

Elisaf, Moses S.; Bairaktari, Eleni Th; Nikolaides, C.; Kakaidi, B.; Tzallas, C. S.; Katsaraki, A.; Pavlidis, Nicholas (2001)

Hormonal therapy plays a central role in the overall treatment of breast cancer. Aromatase inhibitors can inhibit the aromatase enzyme system resulting in a reduction of oestrogens. Letrozole is a non-steroidal aromatase ...

Article

G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting

Briassoulis, E. Ch; Andreopoulou, E.; Ch, F. Tolis; Bairaktari, Eleni Th; Katsaraki, A.; Dimopoulos, M. A.; Fountzilas, George; Seferiadis, C.; Pavlidis, Nicholas (2001)

BACKGROUND. Cancer antigen 15-3 (CA 15-3), a circulating marker that determines secreted products of the polymorphic MUC1 gene, has been established as a convenient tool for monitoring breast carcinoma patients. METHODS. ...

Article

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: A quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial

Pentheroudakis, George; Kalogeras, K. T.; Wirtz, R. M.; Grimani, I.; Zografos, G.; Gogas, H.; Stropp, U.; Pectasides, Dimitrios; Skarlos, Dimosthenis V.; Hennig, G.; Samantas, E.; Bafaloukos, Dimitrios; Papakostas, P.; Kalofonos, H. P.; Pavlidis, Nicholas; Fountzilas, George (2009)

Background Estrogen receptor (ER) and progesterone receptor (PgR) protein expression carry weak prognostic and moderate predictive utility for the outcome of early breast cancer patients on adjuvant chemohormonotherapy. ...

Article

Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: Their prognostic value and role in tumour invasion and progression

Ioachim, E.; Charchanti, A.; Briassoulis, E. Ch; Karavasilis, V.; Tsanou, E.; Arvanitis, D. L.; Agnantis, Niki J.; Pavlidis, Nicholas (2002)

The immunohistochemical expression of the extracellular matrix (ECM) components tenascin (TN), fibronectin (FN), collagen type IV (Coll) and laminin (LN), and their possible relationships were studied in a series of 134 ...

Article

Immunohistochemical expression of superoxide dismutase (MnSOD) anti-oxidant enzyme in invasive breast carcinoma

Tsanou, E.; Ioachim, E.; Briassoulis, E. Ch; Damala, K.; Charchanti, A.; Karavasilis, V.; Pavlidis, Nicholas; Agnantis, Niki J. (2004)

The most important cellular protective mechanisms against oxidative stress are antioxidant enzymes. Their action is based on decomposal of reactive oxygen species (ROS) and their transformation to H2O2. Within the mitochondria ...

Article

Levels of absolute survival benefit for systemic therapies of advanced cancer: A call for standards

Ioannidis, J. P. A.; Pavlidis, Nicholas (2003)

Research on systemic interventions in patients with advanced stage malignancies should be systematised with an emphasis on the absolute gain in survival for the median patient. Such information is most meaningful with ...

Article

Metastatic breast carcinoma confined to bone: Portrait of a clinical entity

Briassoulis, E. Ch; Karavasilis, V.; Kostadima, Lida; Ignatiadis, M.; Fountzilas, George; Pavlidis, Nicholas (2004)

BACKGROUND. The current study was performed to study metastatic breast carcinoma that remains confined to bone. METHODS. The medical notes of 2514 breast carcinoma patients who were treated in 2 academic units over a 20-year ...

Article

Mitoxantrone: An active new agent in the treatment of advanced breast cancer

Stuart-Harris, R. C.; Bozek, T.; Pavlidis, Nicholas; Smith, I. E. (1984)

Sixty-five patients with advanced breast carcinoma were treated with mitoxantrone, an anthracenedione with structural similarities to adriamycin. The series included 26 patients who had received no prior chemotherapy. ...

Article

The neutrophil, not the tumor: Serum CA 15-3 elevation as a result of granulocyte-colony-stimulating factor-induced neutrophil MUC1 overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy

Pentheroudakis, George; Malamou-Mitsi, Vassiliki D.; Briassoulis, E. Ch; Damala, K.; Vassou, A.; Vartholomatos, G.; Kolaitis, N.; Pavlidis, Nicholas (2004)

BACKGROUND. Patients with resected breast carcinoma who received granulocyte-colony-stimulating factor (G-CSF)-supported adjuvant chemotherapy exhibited an increase in their serum CA 15-3 levels. The authors investigated ...

Article

Oral chemotherapy in advanced breast cancer. A reconsideration

Pavlidis, Nicholas (1985)

Article

Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer

Kerbrat, P.; Dieras, V.; Pavlidis, Nicholas; Ravaud, A.; Wanders, J.; Fumoleau, P. (2003)

LU 103793 is a synthetic analogue of Dolastatin 15 that inhibits tubulin polymerisation. The aim of this study was to evaluate the efficacy and tolerability of LU 103793 in patients with metastatic breast cancer who had ...

Article

The prognostic evaluation of tumor angiogenesis in invasive breast carcinoma

Ioachim, E.; Charchanti, A.; Charalabopoulos, K.; Tsanou, E.; Briassoulis, E. Ch; Karavasilis, V.; Pavlidis, Nicholas; Agnantis, Niki J. (2002)

Microvessel density (MVD) was analyzed for associations with clinical and pathological factors as well as with other potential known prognostic factors such as: steroid receptor content (ER, PgR), p53 and proliferation ...

Article

The prognostic value of vascular endothelial growth factor (VEGF) in invasive breast cancer: Correlation with microvessel density (MVD), ER, PgR, p53 and proliferative associated indices (Ki-67, PCNA)

Ioachim, E.; Charchanti, A.; Briassoulis, E. Ch; Karavasilis, V.; Batsis, Ch; Pavlidis, Nicholas; Agnantis, Niki J. (2002)

The formation of new vessels in both primary tumour and in metastasis induce various growth factors included the vascular endothelial growth factors (VEGF). The immunohistochemical expression of vascular endothelial growth ...

Article

Rectal metastases from lobular carcinoma of the breast: Report of a case and literature review

Bamias, A. T.; Baltayiannis, G.; Kamina, S.; Fatouros, M.; Lymperopoulos, E.; Agnantis, Niki J.; Tsianos, Epameinondas; Pavlidis, Nicholas (2001)

Metastatic involvement of the gastrointestinal (G1) tract secondary to breast cancer is rare. Reported herein is the case of a 74-year-old woman with metastatic lobular breast carcinoma to the rectum presenting with ...

Article

Statistical modelling and prognostic analysis in primary breast carcinoma

Vonta, Filia; Karagrigoriou, Alex; Adamou, Adamos K.; Zouvani, Ioanna; Kyriacou, Kyriacos C. (2000)

This work reports, for the first time, the results of the first retrospective study on breast cancer in Cyprus. The study which is based on 197 women with primary breast cancer who have undergone modified radical mastectomy ...

Article

Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors

Greco, F. A.; Pavlidis, Nicholas (2009)

The treatment for patients with unknown primary carcinoma, particularly those with unfavorable prognosis factors, has changed in the last decade, and continues to evolve. Empiric chemotherapy trials reported since 2000 ...